Elimination of multidrug-resistant Proteus mirabilis biofilms using bacteriophages

  • Salwa GomaaEmail author
  • Fathy Serry
  • Hemmat Abdellatif
  • Hisham Abbas
Original Article


Proteus mirabilis is responsible for a wide range of infections that affect the urinary tract, the respiratory tract, burns, wounds and the feet of individuals with diabetes. They are highly resistant to antimicrobial agents, and new therapeutic options are therefore needed to combat this pathogen. The use of bacteriophages is one option that may be useful in treating multidrug-resistant (MDR) Proteus mirabilis infections, especially biofilm-based infections. The aim of this study was to control biofilms formed by MDR Proteus mirabilis using bacteriophages. Proteus mirabilis isolates were identified based on biochemical tests, and their resistance profiles were determined by the disk diffusion method. The biofilm-forming capacity of the isolates was assessed by the spectrophotometric method. Bacteriophages attacking Proteus mirabilis were isolated from sewage. The effect of phage on biofilm formation was investigated by the viable count method. A high rate of drug resistance was found (87.2%). Strong biofilm formation was observed in 80.5% of isolates, while moderate production was found in 19.5%. Five bacteriophages were isolated from sewage and were tested for their ability to eliminate biofilms. Significant disruption of pre-formed biofilms was observed that reached up to 99.9% decrease in the number of viable cells. The use of bacteriophages is considered a promising strategy against the biofilm infections caused by MDR Proteus mirabilis isolates.


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Abbas HA, Gad AI (2014) Eradication of biofilms formed by bacteria isolated from diabetic foot infections by potential antibiofilm agents alone and in combination with ciprofloxacin. Afr J Microbiol Res 8:3882–3892Google Scholar
  2. 2.
    Abbas HA, El-Saysed MA, Ganiny AM, Fattah AA (2018) Antimicrobial resistance patterns of Proteus mirabilis isolates from urinary tract, burn wound and diabetic foot infections. Res J Pharm Tech 11:249–252CrossRefGoogle Scholar
  3. 3.
    Adeolu M, Alnajar S, Naushad S, Gupta RS (2016) Genome-based phylogeny and taxonomy of the ‘Enterobacteriales’: proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Int J Syst Evol Microbiol 66:5575–5599CrossRefGoogle Scholar
  4. 4.
    Afriani R, Rusmana I, Budiarti S (2014) Characterization of Proteus mirabilis lytic phage from Situ Letik River Bogor Indonesia. Int J Innovat Res Sci Eng 2:2347–3207Google Scholar
  5. 5.
    Akova M (2016) Epidemiology of antimicrobial resistance in bloodstream infections. Virulence 7:252–266CrossRefGoogle Scholar
  6. 6.
    Azeredo J, Sutherland IW (2008) The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9:261–266CrossRefGoogle Scholar
  7. 7.
    Carey-Smith GV, Billington C, Cornelius AJ, Hudson JA, Heinemann JA (2006) Isolation and characterization of bacteriophages infecting Salmonella spp. FEMS Microbiol Lett 258:182–186CrossRefGoogle Scholar
  8. 8.
    Carlton RM (1999) Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz) 47:267–274Google Scholar
  9. 9.
    Carson L, Gorman SP, Gilmore BF (2010) The use of lytic bacteriophages in the prevention and eradication of biofilms of Proteus mirabilis and Escherichia coli. FEMS Immunol Med Microbiol 59:447–455CrossRefGoogle Scholar
  10. 10.
    Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A (1999) The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37:1771–1776Google Scholar
  11. 11.
    Cerveny KE, DePaola A, Duckworth DH, Gulig PA (2002) Phage therapy of local and systemic disease caused by Vibrio vulnificus in iron-dextran-treated mice. Infect Immun 70:6251–6262CrossRefGoogle Scholar
  12. 12.
    Chan BK, Abedon ST, Loc-Carrillo C (2013) Phage cocktails and the future of phage therapy. Fut Microbiol 8:769–783CrossRefGoogle Scholar
  13. 13.
    Chen C-Y, Chen Y-H, Lu P-L, Lin W-R, Chen T-C, Lin C-Y (2012) Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. J Microbiol Immunol Infect 45:228–236CrossRefGoogle Scholar
  14. 14.
    Clark JR, March JB (2006) Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials. Trends Biotechnol 24:212–218CrossRefGoogle Scholar
  15. 15.
    CLSI-Clinical and Laboratory Standards Institute (2016) Performance standards for antimicrobial susceptibility testing, CLSI document M100-S-26. CLSI-Clinical and Laboratory Standards Institute, WayneGoogle Scholar
  16. 16.
    Coker C, Poore CA, Li X, Mobley HL (2000) Pathogenesis of Proteus mirabilis urinary tract infection. Microb Infect 2:1497–1505CrossRefGoogle Scholar
  17. 17.
    Cornelissen A, Ceyssens P-J, T’syen J, Van Praet H, Noben J-P, Shaburova OV, Krylov VN, Volckaert G, Lavigne R (2011) The T7-related Pseudomonas putida phage φ15 displays virionassociated biofilm degradation properties. PLoS One 6:e18597CrossRefGoogle Scholar
  18. 18.
    Danis-Wlodarczyk K, Olszak T, Arabski M, Wasik S, Majkowska-Skrobek G, Augustyniak D, Gula G, Briers Y, Jang HB, Vandenheuvel D, Duda KA, Lavigne R, Drulis-Kawa Z (2015) Characterization of the newly isolated lytic bacteriophages KTN6 and KT28 and their efficacy against Pseudomonas aeruginosa biofilm. PLoS One 10:e0127603CrossRefGoogle Scholar
  19. 19.
    Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A (2005) Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 49:2598–2605CrossRefGoogle Scholar
  20. 20.
    Fard RMN, Barton MD, Heuzenroeder MW (2010) Novel Bacteriophages in Enterococcus spp. Curr Microbiol 60:400–406CrossRefGoogle Scholar
  21. 21.
    Ghannad MS, Mohammadi A (2012) Bacteriophage: time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria. Iran J Basic Med Sci 15:693–701Google Scholar
  22. 22.
    Goodridge LD (2010) Designing phage therapeutics. Curr Pharm Biotechnol 11:15–27CrossRefGoogle Scholar
  23. 23.
    Gurnev PA, Oppenheim AB, Winterhalter M, Bezrukov SM (2006) Docking of a single phage lambda to its membrane receptor maltoporin as a time-resolved event. J Mol Biol 359:1447–1455CrossRefGoogle Scholar
  24. 24.
    Gutiérrez D, Vandenheuvel D, Martínez B, Rodríguez A, Lavigne R, García P (2015) Two phages, phiIPLA-RODI and phiIPLA-C1C, lyse mono-and dual-species Staphylococcal biofilms. Appl Environ Microbiol 81:3336–3348CrossRefGoogle Scholar
  25. 25.
    Hall-Stoodley L, Costerton JW, Stoodley P (2004) Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol 2:95–108CrossRefGoogle Scholar
  26. 26.
    Hall-Stoodley L, Stoodley P (2009) Evolving concepts in biofilm infections. Cell Microbiol 11:1034–1043CrossRefGoogle Scholar
  27. 27.
    Harper D, Enright M (2011) Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol 111:1–7CrossRefGoogle Scholar
  28. 28.
    Harrison JJ, Turner RJ, Joo DA, Stan MA, Chan CS, Allan ND, Vrionis HA, Olson ME, Ceri H (2008) Copper and quaternary ammonium cations exert synergistic bactericidal and anti-biofilm activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 52:2870–2881CrossRefGoogle Scholar
  29. 29.
    Ho K (2001) Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era. Perspect Biol Med 44:1–16CrossRefGoogle Scholar
  30. 30.
    Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35:322–332CrossRefGoogle Scholar
  31. 31.
    Jacobsen SM, Shirtliff ME (2011) Proteus mirabilis biofilms and catheter-associated urinary tract infections. Virulence 2:460–465CrossRefGoogle Scholar
  32. 32.
    Jun JW, Kim JH, Shin SP, Han JE, Chai JY, Park SC (2013) Characterization and complete genome sequence of the Shigella bacteriophage pSf-1. Res Microbiol 164:979–986CrossRefGoogle Scholar
  33. 33.
    Karaca B, Akcelik N, Akcelik M (2015) Effects of P22 bacteriophage on Salmonella enterica subsp. enterica serovar Typhimurium DMC4 strain biofilm formation and eradication. Arch Biol Sci 67:1361–1367CrossRefGoogle Scholar
  34. 34.
    Karumidze N, Kusradze I, Rigvava S, Goderdzishvili M, Rajakumar K, Alavidze Z (2013) Isolation and characterisation of lytic bacteriophages of Klebsiella pneumoniae and Klebsiella oxytoca. Curr Microbiol 66:251–258CrossRefGoogle Scholar
  35. 35.
    Koneman E, Winn WC, Allen S, Janda W, Procop G, Schreckenberger P, Woods G (2006) Koneman’s color atlas and textbook of diagnostic microbiology, 6th edn. Lippincott Williams & Wilkins, PennsylvaniaGoogle Scholar
  36. 36.
    Koskella B, Meaden S (2013) Understanding bacteriophage specificity in natural microbial communities. Viruses 5:806–823CrossRefGoogle Scholar
  37. 37.
    Krylov VN (2001) Phagotherapy in terms of bacteriophage genetics: hopes, perspectives, safety, limitations. Genetika 37:869–887Google Scholar
  38. 38.
    Kutateladze M, Adamia R (2010) Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol 28:591–595CrossRefGoogle Scholar
  39. 39.
    Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST (2010) Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69–86CrossRefGoogle Scholar
  40. 40.
    Labrie SJ, Samson JE, Moineau S (2010) Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:317–327CrossRefGoogle Scholar
  41. 41.
    Lehman SM, Donlan RM (2015) Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model. Antimicrob Agents Chemother 59:1127–1137CrossRefGoogle Scholar
  42. 42.
    Lewis K (2001) Riddle of biofilm resistance. Antimicrob Agents Chemother 45:999–1007CrossRefGoogle Scholar
  43. 43.
    Lewis K (2010) Persister cells. Annu Rev Microbiol 64:357–372CrossRefGoogle Scholar
  44. 44.
    Liu M, Deora R, Doulatov SR, Gingery M, Eiserling FA, Preston A, Maskell DJ, Simons RW, Cotter PA, Parkhill J, Miller JF (2002) Reverse transcriptase-mediated tropism switching in Bordetella bacteriophage. Science 295:2091–2094CrossRefGoogle Scholar
  45. 45.
    Loc-Carrillo C, Abedon ST (2011) Pros and cons of phage therapy. Bacteriophage 1:111–114CrossRefGoogle Scholar
  46. 46.
    Lynch AS, Robertson GT (2008) Bacterial and fungal biofilm infections. Annu Rev Med 59:415–428CrossRefGoogle Scholar
  47. 47.
    Melo LD, Veiga P, Cerca N, Kropinski AM, Almeida C, Azeredo J, Sillankorva S (2016) Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections. Front Microbiol 7:1024–1035CrossRefGoogle Scholar
  48. 48.
    Modi SR, Collins JJ, Relman DA (2014) Antibiotics and the gut microbiota. J Clin Invest 124:4212–4218CrossRefGoogle Scholar
  49. 49.
    Morozova V, Kozlova Y, Shedko E, Kurilshikov A, Babkin I, Tupikin A, Yunusova A, Chernonosov A, Baykov I, Capital Kabul CI, Kabilov M, Ryabchikova E, Vlassov V, Tikunova N (2016) Lytic bacteriophage PM16 specific for Proteus mirabilis: a novel member of the genus Phikmvvirus. Arch Virol 161:2457–2472CrossRefGoogle Scholar
  50. 50.
    Morozova V, Kozlova Y, Shedko E, Babkin I, Kurilshikov A, Bokovaya O, Bardashova A, Yunusova A, Tikunov A, Tupikin A, Ushakova T, Ryabchikova E, Tikunova N (2018) Isolation and characterization of a group of new Proteus bacteriophages. Arch Virol 163:2189–2197CrossRefGoogle Scholar
  51. 51.
    Nzakizwanayo J, Hanin A, Alves DR, McCutcheon B, Dedi C, Salvage J, Knox K, Stewart B, Metcalfe A, Clark J (2015) Bacteriophage can prevent encrustation and blockage of urinary catheters by Proteus mirabilis. Antimicrob Agents Chemother 60:1530–1536CrossRefGoogle Scholar
  52. 52.
    Parasion S, Kwiatek M, Gryko R, Mizak L, Malm A (2014) Bacteriophages as an alternative strategy for fighting biofilm development. Pol J Microbiol 63:137–145Google Scholar
  53. 53.
    Perim MC, Borges Jda C, Celeste SR, Orsolin Ede F, Mendes RR, Mendes GO, Ferreira RL, Carreiro SC, Pranchevicius MC (2015) Aerobic bacterial profile and antibiotic resistance in patients with diabetic foot infections. Rev Soc Br Med Trop 48:546–554CrossRefGoogle Scholar
  54. 54.
    Projan S (2004) Phage-inspired antibiotics? Nat Biotechnol 22:167–168CrossRefGoogle Scholar
  55. 55.
    Różalski A, Sidorczyk Z, Kotelko K (1997) Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 61:65–89Google Scholar
  56. 56.
    Rydman PS, Bamford DH (2002) The lytic enzyme of bacteriophage PRD1 is associated with the viral membrane. J Bacteriol 184:104–110CrossRefGoogle Scholar
  57. 57.
    Sekhar S, Vyas N, Unnikrishnan M, Rodrigues G, Mukhopadhyay C (2014) Antimicrobial susceptibility pattern in diabetic foot ulcer: a pilot study. Ann Med Health Sci Res 4:742–745CrossRefGoogle Scholar
  58. 58.
    Shanmugam P, Jeya M, Susan SL (2013) The bacteriology of diabetic foot ulcers, with a special reference to multidrug resistant strains. J Clin Diagn Res 7:441–445Google Scholar
  59. 59.
    Shapiro OH, Kushmaro A (2011) Bacteriophage ecology in environmental biotechnology processes. Curr Opin Biotechnol 22:449–455CrossRefGoogle Scholar
  60. 60.
    Skurnik M, Strauch E (2006) Phage therapy: facts and fiction. Int J Med Microbiol 296:5–14CrossRefGoogle Scholar
  61. 61.
    Stepanović S, Vuković D, Hola V, Bonaventura GD, Djukić S, Ćirković I, Ruzicka F (2007) Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. Acta Pathol Microbiol Immunol Scand B Microbiol 115:891–899CrossRefGoogle Scholar
  62. 62.
    Stewart PS (2002) Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol 292:107–113CrossRefGoogle Scholar
  63. 63.
    Stickler DJ (2014) Clinical complications of urinary catheters caused by crystalline biofilms: something needs to be done. J Intern Med 276:120–129CrossRefGoogle Scholar
  64. 64.
    Sutherland IW, Hughes KA, Skillman LC, Tait K (2004) The interaction of phage and biofilms. FEMS Microbiol Lett 232:1–6CrossRefGoogle Scholar
  65. 65.
    Thompson R (2018) The isolation and characterisation of Proteus mirabilis bacteriophages and their effect on the colonisation and blockage of urinary catheters. (PhD thesis), Faculty of Health and Applied Sciences, University of the West of England, BristolGoogle Scholar
  66. 66.
    Trachoo N (2004) Biofilm removal technique using sands as a research tool for accessing microbial attachment on surface. Songklanakarin J Sci Technol 26:109–115Google Scholar
  67. 67.
    Yah S, Enabulele I, Yusuf E, Eghafona N (2006) Emerging quinolones resistant transfer genes among gram-negative bacteria isolated from faeces of HIV/AIDS patient attending some clinic and hospital in the city of Benin, Edo State, Nigeria. Online J Health Allied Sci 5:61–91Google Scholar
  68. 68.
    Yazdi M, Bouzari M, Ghaemi EA (2018) Isolation and characterization of a lytic bacteriophage (vB_PmiS-TH) and its application in combination with ampicillin against planktonic and biofilm forms of Proteus mirabilis isolated from urinary tract infection. J Mol Microbiol Biotechnol 28:37–46CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Microbiology and Immunology, Faculty of PharmacyZagazig UniversityZagazigEgypt

Personalised recommendations